AMAG Pharmaceuticals Provides Financial and Business Update
Jan 09, 2017 13:02 pm UTC| Business
2016 total revenue increased 45 percent Provides update on Makena® next-generation program Anticipates 2017 GAAP revenue of $620-$670 million, including Makena net sales of $410-$440 million WALTHAM, Mass.,...
Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
Jan 09, 2017 13:02 pm UTC| Business
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E. Dudley, Ph.D.has joined the company as...
Jan 09, 2017 13:02 pm UTC| Business
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (NYSE:GSK) (LSE:GSK) has...
Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study
Jan 09, 2017 13:02 pm UTC| Business
LIVONIA, Mich., Jan. 09, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof of concept efficacy in a...
Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study
Jan 09, 2017 13:02 pm UTC| Business
LIVONIA, Mich., Jan. 09, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof of concept efficacy in a...
Advaxis Provides 2017 Business Outlook
Jan 09, 2017 13:02 pm UTC| Business
PRINCETON, N.J., Jan. 09, 2017 -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today issued its 2017 business outlook to provide an overview of anticipated...
Advaxis Provides 2017 Business Outlook
Jan 09, 2017 13:02 pm UTC| Business
PRINCETON, N.J., Jan. 09, 2017 -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today issued its 2017 business outlook to provide an overview of anticipated...